Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims filed November 9, 2022 are entered.
Claim Objections
Claims 4-27 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims 4-27 have not been further treated on the merits.
Claims 1-27 are pending. Claims 4-27 are withdrawn. Claims 1-3 are examined.
Specification
The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
The specification page 38-39 contains hyperlinks. Please examine the specification for additional hyperlinks.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 1-3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ju et al.(Nature, 2020) in view of Goldstein et al.(Comm. Biol., 2019) and Liao (CN 107760690).
Lu teach the methods of obtaining monoclonal antibody that speicifically binds to a receptor binding domain (RBD) from single B cell of patients infected with novel coronavirus (pages 4, 6). The blood samples from 8 individuals infected with novel coronavirus are obtained. Specific single B cell is separated by RBD probe and the monoclonal antibody of the B cell is cloned and expressed by RT-PCR using a nested primer. 206 antibodies are found to bind to RBD of novel coronavirus. Lu does not teach the method of blood sample from an individual confirmed not to carry the antigen or to carry a reduced amount of the antigen aat a second time after the first time confirmation. Lu does not teach VDJ sequencing transcriptome sequencing of B cell.
Goldstein teach the method of high throughput separation of the single B cell and BDJ sequencing of single cell transcriptome (page 3). Monoclonal anitobyd VH-VL sequence and analysis of B cell (page 9). Expression of the antibody.
Liao teach isolating B cells from a blood sample of individual who are healed and have reduced and isolating the antibody gene (section 2.1-2.2).
It would have been obvious to one of ordinary skill in the art at the time of the invention to include the teaching of Goldstein to isolate the gene sequence with VDJ sequencing and Liao to isolate sample of reduced antigen level into the teaching of Lu teaching of B cell isolate of coronavirus infected patients to isolate antibody. One of ordinary skill in the art would have been motivated to incorporate the teaching of Goldstein because of the improvement in identification of the VDJ sequencing of B cells. One of ordinary skill in the art would have been motivated to incorporate the teaching of Liao because of ability of sequencing to bypass isolating antibody from serum after infection period has reduced antibody titer. Furthermore, it is obvious to combine prior art techniques which are well known to yield predictable results.
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL D PAK whose telephone number is (571)272-0879. The examiner can normally be reached on flexible time.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached on 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MICHAEL D PAK/Primary Examiner, Art Unit 1674